<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">884</article-id><article-id pub-id-type="doi">10.17650/2222-1468-2023-13-2-10-17</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of regional relapses in the central zone after surgical treatment of highly differentiated thyroid cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности регионарных рецидивов в центральной зоне после хирургического лечения высокодифференцированного рака щитовидной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6007-0885</contrib-id><name-alternatives><name xml:lang="en"><surname>Gogieva</surname><given-names>E. Kh.</given-names></name><name xml:lang="ru"><surname>Гогиева</surname><given-names>Э. Х.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Eliza Hampashevna Gоgieva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>Элиза Хампашевна Гогиева</p><p>115522 Москва, Каширское шоссе, 24</p></bio><email>elizagogieva535@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5421-5985</contrib-id><name-alternatives><name xml:lang="en"><surname>Romanov</surname><given-names>I. S.</given-names></name><name xml:lang="ru"><surname>Романов</surname><given-names>И. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9066-5190</contrib-id><name-alternatives><name xml:lang="en"><surname>Bokhyan</surname><given-names>V. Yu.</given-names></name><name xml:lang="ru"><surname>Бохян</surname><given-names>В. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6796-0968</contrib-id><name-alternatives><name xml:lang="en"><surname>Ignatova</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Игнатова</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p><p>6 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p><p>117198 Москва, ул. Миклухо-Маклая, 6</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3629-8438</contrib-id><name-alternatives><name xml:lang="en"><surname>Gabrava</surname><given-names>M. M.</given-names></name><name xml:lang="ru"><surname>Габрава</surname><given-names>М. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3095-0088</contrib-id><name-alternatives><name xml:lang="en"><surname>Zarenkova</surname><given-names>A. K.</given-names></name><name xml:lang="ru"><surname>Заренкова</surname><given-names>А. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Bld. 1, 9 Parkovy proezd, Kuznechiki village, Podolsk 142110</p></bio><bio xml:lang="ru"><p>142110 Подольск, пос. Кузнечики, Парковый проезд, 9, корп. 1</p></bio><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-6927-1966</contrib-id><name-alternatives><name xml:lang="en"><surname>Safonova</surname><given-names>A. B.</given-names></name><name xml:lang="ru"><surname>Сафонова</surname><given-names>А. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-8502-1256</contrib-id><name-alternatives><name xml:lang="en"><surname>Batyrov</surname><given-names>K. A.</given-names></name><name xml:lang="ru"><surname>Батыров</surname><given-names>К. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Podolsk Regional Clinical Hospital Center for Outpatient Cancer Care</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Подольская областная клиническая больница», Центр амбулаторной онкологической помощи</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-09-13" publication-format="electronic"><day>13</day><month>09</month><year>2023</year></pub-date><volume>13</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>10</fpage><lpage>17</lpage><history><date date-type="received" iso-8601-date="2023-09-12"><day>12</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-12"><day>12</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Gogieva E.K., Romanov I.S., Bokhyan V.Y., Ignatova A.V., Gabrava M.M., Zarenkova A.K., Safonova A.B., Batyrov K.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Гогиева Э.Х., Романов И.С., Бохян В.Ю., Игнатова А.В., Габрава М.М., Заренкова А.К., Сафонова А.Б., Батыров К.А.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Gogieva E.K., Romanov I.S., Bokhyan V.Y., Ignatova A.V., Gabrava M.M., Zarenkova A.K., Safonova A.B., Batyrov K.A.</copyright-holder><copyright-holder xml:lang="ru">Гогиева Э.Х., Романов И.С., Бохян В.Ю., Игнатова А.В., Габрава М.М., Заренкова А.К., Сафонова А.Б., Батыров К.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/884">https://ogsh.abvpress.ru/jour/article/view/884</self-uri><abstract xml:lang="en"><p><bold>Introduction</bold>. Thyroid cancer is the most common malignant tumor of the endocrine system and comprises 33 % of malignant neoplasms of the head and neck. first echelon lymph nodes affected by this pathology are located in the central area of the neck. The metastatic process further advances into the lymph nodes in the lateral tissues of the neck. Currently, there is no consensus on the effectiveness of prophylactic central lymph node dissection and no conclusive criteria determining the risk of recurrence in the central zone.</p><p><bold>Aim.</bold> The assessment of factors influencing the risk of regional recurrence in the central zone.</p><p><bold>Materials and methods.</bold> The study included 30 patients with highly differentiated thyroid cancer, in whom metastatic nodes in the central zone were identified and verified during primary treatment. All patients previously underwent unilateral or 2-sided central lymph node dissection in various institutions. During the period of dynamic observation, these patients revealed regional recurrence in the central zone. patients were observed and treated for recurrence at the National medical Research Center of Oncology named after N.N. Blokhin of the ministry of Health of Russia.</p><p><bold>Results.</bold> primary surgical treatment in a specialized oncological institution was performed in 21 (70 %) patients, in a general surgical medical institution – in 7 (23.3 %), in an endocrinological institution – in 2 (6.7 %) patients. when assessing the influence of the morphological type and variant of thyroid cancer on the risk of developing regional recurrence,  no  statistical  significance  was  found.  No  statistically  significant  factors  were  found  in  the  analysis  of  the influence of characteristics of the primary tumor, such as tumor size, multifocal lesion, vascular invasion, extrathyroidal spread, on the risk of regional recurrence. In 16 (53.3 %) patients, recurrence occurred in the paratracheal zone of the ipsilateral side, in 7 (23.3 %) patients in the paratracheal zone of the contralateral side, bilateral lesions were observed in 2 (6.67 %) cases. 3 (10 %) patients were diagnosed with transient parathyroid insufficiency, 1 (3.3 %) – permanent parathyroid insufficiency, 1 (3.3 %) – hematoma in the area of the postoperative wound, patient, 2 (6.6 %) – injury to the recurrent laryngeal nerve.</p><p><bold>Conclusion</bold>. Residual metastatic lymph nodes after previous surgical treatment are the reason for performing a second operation, which carries both the risks of postoperative complications and the psychological burden on the patient. Thus, an adequate and radically performed primary surgical intervention is the key to reducing regional recurrences.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Рак щитовидной железы является наиболее распространенной злокачественной опухолью эндокринной системы и составляет 33 % злокачественных новообразований головы и шеи. лимфатические узлы первого порядка, поражаемые при данной патологии, расположены в центральном отделе шеи. В дальнейшем метастатический процесс распространяется на лимфатические узлы боковой клетчатки шеи. На сегодняшний день отсутствует консенсус по вопросу эффективности профилактической центральной лимфодиссекции и не определены убедительные критерии, влияющие на риск развития рецидива в центральной зоне.</p><p><bold>Цель исследования</bold> – оценка факторов, влияющих на риск развития регионарного рецидива в центральной зоне после хирургического лечения высокодифференцированного рака щитовидной железы.</p><p><bold>Материалы и методы</bold>. В группу исследования включены 30 пациентов с высокодифференцированным раком щитовидной железы, у которых при первичном лечении были выявлены и верифицированы метастатические узлы в центральной зоне. Всем больным ранее выполнена односторонняя или двусторонняя центральная лимфодиссекция в различных учреждениях. В период динамического наблюдения у этих пациентов выявлен регионарный рецидив в центральной зоне. больные наблюдались и получали лечение в Национальном медицинском исследовательском центре онкологии им. Н.Н. блохина Минздрава России.</p><p><bold>Результаты.</bold> первичное хирургическое лечение в специализированном онкологическом учреждении выполнено 21 (70 %) пациенту, в общехирургическом лечебном учреждении – 7 (23,3 %), в лечебном учреждении эндокринологического профиля – 2 (6,7 %). при оценке влияния морфологического типа и варианта рака щитовидной железы на риск развития регионарного рецидива статистической значимости не выявлено. В ходе анализа влияния на риск возникновения регионарного рецидива характеристик первичной опухоли, таких как размер опухоли, мультифокальное поражение, сосудистая инвазия, экстратиреоидное распространение, статистически значимых факторов не обнаружено. у 16 (53,3 %) пациентов рецидив возник в паратрахеальной зоне ипсилатеральной стороны, у 7 (23,3 %) – в паратрахеальной зоне контралатеральной стороны, двустороннее поражение отмечено в 2 (6,67 %) случаях. после выполнения повторной операции у 3 (10 %) больных выявлена преходящая паратиреоидная недостаточность, у 1 (3,3 %) – постоянная паратиреоидная недостаточность, у 1 (3,3 %) – гематома в области послеоперационной раны, у 2 (6,6 %) – травматизация возвратного гортанного нерва.</p><p><bold>Заключение.</bold> Остаточные метастатические лимфатические узлы после проведенного ранее хирургического лечения являются причиной выполнения повторной операции, которая несет в себе как риск развития послеоперационных осложнений, так и психологическую нагрузку на пациента. таким образом, адекватное и радикально выполненное первичное хирургическое вмешательство является ключом к снижению частоты регионарных рецидивов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>highly differentiated thyroid cancer</kwd><kwd>regional relapse</kwd><kwd>central lymph node dissection</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>высокодифференцированный рак щитовидной железы</kwd><kwd>регионарный рецидив</kwd><kwd>центральная лимфодиссекция</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006;106(3):524–31. DOI: 10.1002/cncr.21653</mixed-citation><mixed-citation xml:lang="ru">Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006;106(3):524–31. DOI: 10.1002/cncr.21653</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI: 10.1016/s0140-6736(03)12488-9</mixed-citation><mixed-citation xml:lang="ru">Sherman S.I. Thyroid carcinoma. Lancet 2003;361(9356):501–11. DOI: 10.1016/s0140-6736(03)12488-9</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Asimakopoulos P., Nixon I.J., Shaha A.R. Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes. Clin Oncol 2017;29(5):283–9. DOI: 10.1016/j.clon.2017.01.001</mixed-citation><mixed-citation xml:lang="ru">Asimakopoulos P., Nixon I.J., Shaha A.R. Differentiated and Medullary Thyroid Cancer: Surgical Management of Cervical Lymph Nodes. Clin Oncol 2017;29(5):283–9. DOI: 10.1016/j.clon.2017.01.001</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Tiroidin Fonksiyonel ve Cerrahi Anatomisi. Ed. by A. Isgör, M. Uludağ, A. Isgör, M. Uludağ. Tiroit. 1st edn. Istanbul: Nobel Tip Kitabevleri, 2013. Pp. 775–800.</mixed-citation><mixed-citation xml:lang="ru">Tiroidin Fonksiyonel ve Cerrahi Anatomisi. Ed. by A. Isgör, M. Uludağ, A. Isgör, M. Uludağ. Tiroit. 1st edn. Istanbul: Nobel Tip Kitabevleri, 2013. Pp. 775–800.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Kouvaraki M.A., Shapiro S.E., Fornage B.D. et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134(6):946–54. DOI: 10.1016/s0039-6060(03)00424-0</mixed-citation><mixed-citation xml:lang="ru">Kouvaraki M.A., Shapiro S.E., Fornage B.D. et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134(6):946–54. DOI: 10.1016/s0039-6060(03)00424-0</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. 6Chow S.M., Law S.C., Chan J.K. et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40. DOI: 10.1002/cncr.11442</mixed-citation><mixed-citation xml:lang="ru">6Chow S.M., Law S.C., Chan J.K. et al. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40. DOI: 10.1002/cncr.11442</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Shaha A.R. Prophylactic central compartment dissection in thyroid cancer: a new avenue of debate. Surgery 2009;46(6):1224–7. DOI: 10.1016/j.surg.2009.10.020</mixed-citation><mixed-citation xml:lang="ru">Shaha A.R. Prophylactic central compartment dissection in thyroid cancer: a new avenue of debate. Surgery 2009;46(6):1224–7. DOI: 10.1016/j.surg.2009.10.020</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004;135(2):139–48. DOI: 10.1016/s0039-6060(03)00384-2</mixed-citation><mixed-citation xml:lang="ru">Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004;135(2):139–48. DOI: 10.1016/s0039-6060(03)00384-2</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Snow G.B., Patel P., Leemans C.R., Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol 1992;249(4):187–94. DOI: 10.1007/BF00178467</mixed-citation><mixed-citation xml:lang="ru">Snow G.B., Patel P., Leemans C.R., Tiwari R. Management of cervical lymph nodes in patients with head and neck cancer. Eur Arch Otorhinolaryngol 1992;249(4):187–94. DOI: 10.1007/BF00178467</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Moo T.A., McGill J., Allendorf J. et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg 2010;34(6):1187–91. DOI: 10.1007/s00268-010-0418-3</mixed-citation><mixed-citation xml:lang="ru">Moo T.A., McGill J., Allendorf J. et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg 2010;34(6):1187–91. DOI: 10.1007/s00268-010-0418-3</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Forest V.I., Clark J.R., Ebrahimi A. et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg 2011;253(1):123–30. DOI: 10.1097/SLA.0b013e3181fc9644</mixed-citation><mixed-citation xml:lang="ru">Forest V.I., Clark J.R., Ebrahimi A. et al. Central compartment dissection in thyroid papillary carcinoma. Ann Surg 2011;253(1):123–30. DOI: 10.1097/SLA.0b013e3181fc9644</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Amin M.B., Greene F.L., Edge S.B. et al. The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9. DOI: 10.3322/caac.21388</mixed-citation><mixed-citation xml:lang="ru">Amin M.B., Greene F.L., Edge S.B. et al. The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9. DOI: 10.3322/caac.21388</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.</mixed-citation><mixed-citation xml:lang="ru">Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Carty S.E., Cooper D.S., Doherty G.M. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19(11):1153–8. DOI: 10.1089/thy.2009.0159</mixed-citation><mixed-citation xml:lang="ru">Carty S.E., Cooper D.S., Doherty G.M. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19(11):1153–8. DOI: 10.1089/thy.2009.0159</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Haugen B.R., Alexander E.K., Bible K.C. el al. American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="ru">Haugen B.R., Alexander E.K., Bible K.C. el al. American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26(1):1–133. DOI: 10.1089/thy.2015.0020</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Takami H., Ito Y., Okamoto T., Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg 2010;35(1):111–21. DOI:10.1007/s00268-010-0832-6</mixed-citation><mixed-citation xml:lang="ru">Takami H., Ito Y., Okamoto T., Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg 2010;35(1):111–21. DOI:10.1007/s00268-010-0832-6</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. British Thyroid Association. Guidelines for the management of thyroid cancer, 2nd edn. 2007. Available at: http://www.british-thyroidassociation.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf</mixed-citation><mixed-citation xml:lang="ru">British Thyroid Association. Guidelines for the management of thyroid cancer, 2nd edn. 2007. Available at: http://www.british-thyroidassociation.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Adam M.A., Pura J., Gu L. et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 2014;260(4):601–5. DOI: 10.1097/SLA.0000000000000925</mixed-citation><mixed-citation xml:lang="ru">Adam M.A., Pura J., Gu L. et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 2014;260(4):601–5. DOI: 10.1097/SLA.0000000000000925</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Nixon I.J., Wang L.Y., Ganly I. et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. Br J Surg 2016;103(3):218–25. DOI: 10.1002/bjs.10036</mixed-citation><mixed-citation xml:lang="ru">Nixon I.J., Wang L.Y., Ganly I. et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. Br J Surg 2016;103(3):218–25. DOI: 10.1002/bjs.10036</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Zhao W., You L., Hou X. et al. The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: a systematic review and meta-analysis: pCND for the locoregional recurrence of papillary thyroid cancer. Ann Surg Oncol 2017;24(8):2189–98. DOI: 10.1245/s10434-016-5691-4</mixed-citation><mixed-citation xml:lang="ru">Zhao W., You L., Hou X. et al. The effect of prophylactic central neck dissection on locoregional recurrence in papillary thyroid cancer after total thyroidectomy: a systematic review and meta-analysis: pCND for the locoregional recurrence of papillary thyroid cancer. Ann Surg Oncol 2017;24(8):2189–98. DOI: 10.1245/s10434-016-5691-4</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Chen L., Wu Y.H., Lee C.H. et al. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg 2018;42(9):2846–57. DOI: 10.1007/s00268-018-4547-4</mixed-citation><mixed-citation xml:lang="ru">Chen L., Wu Y.H., Lee C.H. et al. Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis. World J Surg 2018;42(9):2846–57. DOI: 10.1007/s00268-018-4547-4</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Zhao W.J., Luo H., Zhou Y.M. et al. Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: an updated meta-analysis. Eur J Surg Oncol 2017;43(11):1989–2000. DOI: 10.1016/j.ejso.2017.07.008</mixed-citation><mixed-citation xml:lang="ru">Zhao W.J., Luo H., Zhou Y.M. et al. Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: an updated meta-analysis. Eur J Surg Oncol 2017;43(11):1989–2000. DOI: 10.1016/j.ejso.2017.07.008</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Su H., Li Y. Prophylactic central neck dissection and local recurrence in papillary thyroid microcarcinoma: a meta-analysis. Braz J Otorhinolaryngol 2019;85(2):237–43. DOI: 10.1016/j.bjorl.2018.05.004</mixed-citation><mixed-citation xml:lang="ru">Su H., Li Y. Prophylactic central neck dissection and local recurrence in papillary thyroid microcarcinoma: a meta-analysis. Braz J Otorhinolaryngol 2019;85(2):237–43. DOI: 10.1016/j.bjorl.2018.05.004</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Raffaelli M., Crea C.D., Sessa L. et al. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. Surgery 2012;152(6):957–64. DOI: 10.1016/j.surg.2012.08.053</mixed-citation><mixed-citation xml:lang="ru">Raffaelli M., Crea C.D., Sessa L. et al. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. Surgery 2012;152(6):957–64. DOI: 10.1016/j.surg.2012.08.053</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Dobrinja C., Troian M., Cipolat M.T. et al. Rationality in prophylactic central neck dissection in clinically node-negative (Cn0) papillary thyroid carcinoma: is there anything more to say? A decade experience in a single-center. Int J Surg 2017;41(Suppl. 1):S40–7. DOI: 10.1016/j.ijsu.2017.01.113</mixed-citation><mixed-citation xml:lang="ru">Dobrinja C., Troian M., Cipolat M.T. et al. Rationality in prophylactic central neck dissection in clinically node-negative (Cn0) papillary thyroid carcinoma: is there anything more to say? A decade experience in a single-center. Int J Surg 2017;41(Suppl. 1):S40–7. DOI: 10.1016/j.ijsu.2017.01.113</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Kim S.K., Woo J.W., Lee J.H. et al. Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution. J Am Coll Surg 2016;222(5):853–64. DOI: 10.1016/j.jamcollsurg.2016.02.001</mixed-citation><mixed-citation xml:lang="ru">Kim S.K., Woo J.W., Lee J.H. et al. Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution. J Am Coll Surg 2016;222(5):853–64. DOI: 10.1016/j.jamcollsurg.2016.02.001</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. Viola D., Materazzi G., Valerio L. et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015;100(4):1316–24. DOI: 10.1210/jc.2014-3825</mixed-citation><mixed-citation xml:lang="ru">Viola D., Materazzi G., Valerio L. et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015;100(4):1316–24. DOI: 10.1210/jc.2014-3825</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. White M.L., Doherty G.M. Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir 2007;62(5):383–93.</mixed-citation><mixed-citation xml:lang="ru">White M.L., Doherty G.M. Level VI lymph node dissection for papillary thyroid cancer. Minerva Chir 2007;62(5):383–93.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Raffaelli M., Crea C.D., Sessa L. et al. Modulating the extension of thyroidectomy in patients with papillary thyroid carcinoma preoperatively eligible for lobectomy: reliability of ipsilateral central neck dissection. Endocrine 2021;72(2):437–44. DOI: 10.1007/s00268-013-2089-3</mixed-citation><mixed-citation xml:lang="ru">Raffaelli M., Crea C.D., Sessa L. et al. Modulating the extension of thyroidectomy in patients with papillary thyroid carcinoma preoperatively eligible for lobectomy: reliability of ipsilateral central neck dissection. Endocrine 2021;72(2):437–44. DOI: 10.1007/s00268-013-2089-3</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Hartl D.M., Mamelle E., Borget I. et al. Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg 2013;37(8):1951–8. DOI: 10.1007/s00268-013-2089-3</mixed-citation><mixed-citation xml:lang="ru">Hartl D.M., Mamelle E., Borget I. et al. Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg 2013;37(8):1951–8. DOI: 10.1007/s00268-013-2089-3</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Eun Y.G., Lee Y.C., Kwon K.H. Predictive factors of contralateral paratracheal lymph node metastasis in papillary thyroid cancer: prospective multicenter study. Otolaryngol Head Neck Surg 2014;150(2):210–5. DOI: 10.1177/0194599813514726</mixed-citation><mixed-citation xml:lang="ru">Eun Y.G., Lee Y.C., Kwon K.H. Predictive factors of contralateral paratracheal lymph node metastasis in papillary thyroid cancer: prospective multicenter study. Otolaryngol Head Neck Surg 2014;150(2):210–5. DOI: 10.1177/0194599813514726</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Lee K.E., Chung I.Y., Kang E. et al. Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: patterns and predictive factors of nodal metastasis. Head Neck 2013;35(5):672–6. DOI: 10.1002/hed.23016</mixed-citation><mixed-citation xml:lang="ru">Lee K.E., Chung I.Y., Kang E. et al. Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: patterns and predictive factors of nodal metastasis. Head Neck 2013;35(5):672–6. DOI: 10.1002/hed.23016</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Koo B.S., Choi E.C., Yoon Y.H. et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 2009;249(5):840–4. DOI: 10.1097/SLA.0b013e3181a40919</mixed-citation><mixed-citation xml:lang="ru">Koo B.S., Choi E.C., Yoon Y.H. et al. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg 2009;249(5):840–4. DOI: 10.1097/SLA.0b013e3181a40919</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Chen Q., Liu Y., Lu W. et al. Pretracheal lymph node subdivision in predicting contralateral central lymph node metastasis for unilateral papillary thyroid carcinoma: preliminary results. Front Endocrinol (Lausanne) 2022;13:921845. DOI: 10.3389/fendo.2022.921845</mixed-citation><mixed-citation xml:lang="ru">Chen Q., Liu Y., Lu W. et al. Pretracheal lymph node subdivision in predicting contralateral central lymph node metastasis for unilateral papillary thyroid carcinoma: preliminary results. Front Endocrinol (Lausanne) 2022;13:921845. DOI: 10.3389/fendo.2022.921845</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Wei T., Chen R., Zou X. et al. Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma. Eur J Surg Oncol 2015;41(6):746–50. DOI: 10.1016/j.ejso.2015.02.013</mixed-citation><mixed-citation xml:lang="ru">Wei T., Chen R., Zou X. et al. Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma. Eur J Surg Oncol 2015;41(6):746–50. DOI: 10.1016/j.ejso.2015.02.013</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Yoo H.S., Shin M.C., Ji Y.B. et al. Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma: comparison of unilateral versus bilateral central neck dissection. Asian J Surg 2018;41(4):363–9. DOI: 10.1016/j.asjsur.2017.03.002</mixed-citation><mixed-citation xml:lang="ru">Yoo H.S., Shin M.C., Ji Y.B. et al. Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma: comparison of unilateral versus bilateral central neck dissection. Asian J Surg 2018;41(4):363–9. DOI: 10.1016/j.asjsur.2017.03.002</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Loyo M., Tufano R.P., Gourin C.G. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 2013;123(8):2056–63. DOI: 10.1002/lary.23923</mixed-citation><mixed-citation xml:lang="ru">Loyo M., Tufano R.P., Gourin C.G. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope 2013;123(8):2056–63. DOI: 10.1002/lary.23923</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Sosa J.A., Bowman H.M., Tielsch J.M. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30. DOI: 10.1097/00000658-199809000-00005</mixed-citation><mixed-citation xml:lang="ru">Sosa J.A., Bowman H.M., Tielsch J.M. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228(3):320–30. DOI: 10.1097/00000658-199809000-00005</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. Schneider D.F., Ojomo K.A., Chen H., Sippel R.S. Remnant uptake as a postoperative oncologic quality indicator. Thyroid 2013;23(10):1269–76. DOI: 10.1089/thy.2012.0451</mixed-citation><mixed-citation xml:lang="ru">Schneider D.F., Ojomo K.A., Chen H., Sippel R.S. Remnant uptake as a postoperative oncologic quality indicator. Thyroid 2013;23(10):1269–76. DOI: 10.1089/thy.2012.0451</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">40. Popadich A., Levin O., Lee J.C. et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 2011;150(6):1048–57. DOI: 10.1016/j.surg.2011.09.003</mixed-citation><mixed-citation xml:lang="ru">Popadich A., Levin O., Lee J.C. et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 2011;150(6):1048–57. DOI: 10.1016/j.surg.2011.09.003</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">41. Leboulleux S., Rubino C., Baudin E. et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90(10):5723–9. DOI: 10.1210/jc.2005-0285</mixed-citation><mixed-citation xml:lang="ru">Leboulleux S., Rubino C., Baudin E. et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90(10):5723–9. DOI: 10.1210/jc.2005-0285</mixed-citation></citation-alternatives></ref></ref-list></back></article>
